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Hospital de Santa Marta, CHLC, NOVA University, Lisbon, Portugal
Erasmus University Medical Center, Rotterdam, The NetherlandsAfter endovascular aneurysm repair (EVAR), an enlarging
aneurysm is a concern as it suggests continued pressure and
persistent risk of rupture. Improved visualization of endo-
leaks is therefore desirable, offering, as an alternative to
open conversion, therapeutic targets to reverse the ten-
dency for growth. In previous work by Habets et al., blood
pool agents have been successfully used for identiﬁcation of
occult endoleaks.1 The present study by the same group
nicely illustrates the use of a weak albumin binding contrast
magnetic resonance imaging (MRI) technique that may
improve the capacity to detect and better visualize type II
endoleaks.2
As the study focused on patients with growing aneu-
rysms, inherently creating a selection bias, the true inci-
dence of “occult” endoleaks in patients with stable or
shrinking aneurysms remains unknown. The absence of
formal validation against a gold standard also hinders
determination of the sensitivity and predictive value of this
new technique. However, these limitations do not invalidate
the ﬁndings.
What remains to be determined is the implication of the
endoleaks newly detected on magnetic resonance angiog-
raphy. It appears undisputed that a newly found type I or III
endoleak warrants repair, and therefore identifying them is
most valuable. However, in only 11 of 29 patients did the
MRI actually detect an endoleak not identiﬁed on standard
computed tomography angiography surveillance, and the
majority were interpreted as type II. In a meta-analysis by
Sidloff et al., only 0.04% of patients suffered from rupture
allegedly attributed to a type II endoleak.3 Also, it has
recently been suggested that patients with a type II endo-
leak detected by standard methods may even have
improved survival and equivalent aneurysm related
mortality.4DOI of original article: http://dx.doi.org/10.1016/j.ejvs.2015.04.008
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http://dx.doi.org/10.1016/j.ejvs.2015.06.021The actual effect of invasive therapy is unclear e inter-
vention directed at the occlusion of type II endoleaks in the
11 patients with previously undetected endoleaks was
either unsuccessful or the duration of follow up was too
short to render conclusive results. As MRI was not per-
formed post-intervention, the actual failure rate may be
even higher. Most importantly, no ruptures were identiﬁed.
Finally, one more observation should be stressed: in 10% of
patients, the cause for continued expansion was not
determined, reﬂecting the lack of knowledge on the
mechanisms of post-implant growth.
In conclusion, novel methods to improve visualization of
endoleaks may be useful in some cases, but the added value
and implications should be thoroughly assessed before
generalization. Further research focusing on validation of
the diagnostic tool and on the outcome of treatment of
“newly revealed” endoleaks is necessary.REFERENCES
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